Terns Pharmaceuticals, Inc.

NasdaqGS TERN

Terns Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -32.76%

Terns Pharmaceuticals, Inc. Return on Equity (ROE) is -32.76% for the Trailing 12 Months (TTM) ending September 30, 2024, a -5.72% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Terns Pharmaceuticals, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -30.99%.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
Loading...
NasdaqGS: TERN

Terns Pharmaceuticals, Inc.

CEO Ms. Amy L. Burroughs M.B.A.
IPO Date Feb. 5, 2021
Location United States
Headquarters 1065 East Hillsdale Boulevard
Employees 66
Sector Health Care
Industries
Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Similar companies

HOOK

HOOKIPA Pharma Inc.

USD 1.86

4.49%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

ELDN

Eledon Pharmaceuticals, Inc.

USD 3.71

-4.63%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.56

-1.89%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

PDSB

PDS Biotechnology Corporation

USD 1.39

-2.11%

StockViz Staff

January 15, 2025

Any question? Send us an email